Myasthenic crisis: Guidelines for prevention and treatment

Journal of the Neurological Sciences

Volumn 261, Issue 1-2, 2007, Pages 127-133

  Jani Acsadi, Agnes ^a   Lisak, Robert P ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Corticosteroids; Myasthenic crisis; Plasma exchange

Indexed keywords

3,4 DIAMINOPYRIDINE; AZATHIOPRINE; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EDROPHONIUM; GUANIDINE; HYDROCORTISONE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; MEPREDNISONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; PREDNISONE; PYRIDOSTIGMINE; STEROID; TRIAMCINOLONE;

ARTICLE; ASSISTED VENTILATION; BLOOD GAS ANALYSIS; CHILL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIAGNOSTIC TEST; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; ELECTROMYOGRAPHY; HEADACHE; HEART DISEASE; HUMAN; HYPERTENSION; IMMUNOTHERAPY; INTERMETHOD COMPARISON; KIDNEY FAILURE; LABORATORY TEST; LOW DRUG DOSE; MYALGIA; MYASTHENIA; MYASTHENIA GRAVIS; MYOPATHY; PLASMAPHERESIS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RESPIRATORY FAILURE; SERUM SICKNESS; SYMPTOMATOLOGY; THROMBOSIS; THYMECTOMY;

ADRENAL CORTEX HORMONES; CHOLINESTERASE INHIBITORS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOTHERAPY; MYASTHENIA GRAVIS; NEUROMUSCULAR JUNCTION; PLASMA EXCHANGE; PRACTICE GUIDELINES;

EID: 34548171625     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2007.04.045     Document Type: Article

References (84)

1. Watson D.F., and Lisak R.P. Myasthenia gravis: an overview. In: Lisak R.P. (Ed). Handbook of myasthenia gravis and myasthenic syndromes vol. 1 (1994), Marcel Dekker, NY 1-21
2. Myasthenia Gravis. Htpp://www.MGFA.com Accessed June 2005.
3. Lisak R.P. Myasthenia gravis. In: Kruse J.A., Fink M.P., and Carlson R.W. (Eds). Saunders manual of critical care vol. 87 (2003), Saunders, PA 304-306
4. Oosterhuis H.J.G.H. The natural course of myasthenia gravis: a long-term follow-up study. J Neurol Neurosurg Psychiatry 52 10 (1989) 1121-1127
5. Phillips L.H. The epidemiology of myasthenia gravis. Semin Neurol 24 1 (2004) 17-20
6. Kuks J.B.M., and Oosterhuis H.J.G. Clinical presentation and epidemiology of myasthenia gravis. In: Kaminski H.J. (Ed). Current clinical neurology: myasthenia gravis and related disorders vol. 3 (2003), Humana Press Inc, Totova, NJ 93-114
7. Mantegazza R., Baggi F., Antozzi C., Confalonieri P., Morandi L., Bernasconi P., et al. Myasthenia gravis (MG): epidemiological data and prognostic factors. Ann NY Acad Sci 998 (2003) 413-423
8. Matsuda M., Dohi-Iihima N., Nakamura A., Sekijima Y., Morita H., Matsuzawa S., et al. Increase in incidence of elderly-onset patients with myasthenia gravis in Nagano Prefecture, Japan. Intern Med 44 6 (2005) 572-577
9. Thomas C.E., Mayer S.A., Gangor Y., Swarup R., Webster E.A., Chang I., et al. Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology 48 (1997) 1253-1260
10. Elechi C.A., Shah A., and Lisak R.P. Infections occurring in hospitalized myasthenia gravis patients. Ann NY Acad Sci 681 (1993) 561-562
11. Argov Z., and Wirgun I. Drugs and the neuromuscular junction: pharmacotherapy of transmission disorders and drug-induced myasthenic syndromes. In: Lisak (Ed). Handbook of myasthenia gravis and myasthenic syndromes (1994), Marcel Dekker, New York 295-320
12. Pascuzzi R.M. Medications and myasthenia gravis: a reference for health care professionals. Htpp://www.myasthenia.org/drugs/reference.htm.
13. Lisak R.P. Myasthenia gravis. Curr Treat Options Neurol 1 (1999) 239-250
14. Juel V.C., and Massey J.M. Autoimmune myasthenia gravis: recommendations for treatment and immunologic modulation. Curr Treat Options Neurol 7 1 (2005) 3-14
15. Juel V.C. Myasthenia gravis: management of myasthenic crisis and perioperative care. Semin Neurol 24 1 (2004) 75-81
16. Keesey J.C. "Crisis" in myasthenia gravis: an historical perspective. Muscle Nerve 26 (2002) 1-3
17. Keesey J.C. Clinical evaluation and management of myasthenia gravis. Muscle Nerve 29 (2004) 484-505
18. Zhou L., McConville J., Chaudhry V., Adams R.N., Skolasky R.L., Vincent A., et al. Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients. Muscle Nerve 30 1 (2004) 55-60
19. Stickler D.E., Massey J.M., and Sanders D.B. MuSK-antibody positive myasthenia gravis: clinical and electrodiagnostic patterns. Clin Neurophysiol 116 9 (Sep 2005) 2065-2068
20. Seybold M.E. Treatment of myasthenia gravis. In: Engel A.G. (Ed). Myasthenia gravis and myasthenic disorders vol. 8 (1999), Oxford University Press 167-201
21. Ahmed S., Kirmani J.F., Janjua N., AlKawi A., Khatri I., Yahia A.M., et al. Curr Treat Options Neurol 7 (2005) 129-141
22. Kissel J.T., Franklin G.M., and and the Quality Standards Subcommittee of the American Academy of Neurology. A call to arms. Neurology 55 (2000) 3-4
23. Jaretzki III A., Barohn R.J., Ernstoff R.M., Kaminski H.J., Keesey J.C., Penn A.S., et al. Task Force of the Medical Scientific Advisory Board of the Mysthenia Gravis Foundation of America. Myasthenia gravis: recommendations for clinical research standards. Neurology 55 1 (2000) 16-23
24. Provencio J.J., Bleck T.P., and Connors Jr. A.F. Update in non-pulmonary critical care. Am J Respir Crit Care Med 164 (2001) 341-345
25. Janjua N., and Mayer S.A. Myasthenic crisis. In: Suarez J.I. (Ed). Critical care neurology and neurosurgery (2004), Humana Press, New Jersey 469-480
26. Bedlock R.S., and Sanders D.B. How to handle myasthenic crisis. Essential steps in patient care. Postgrad Med 107 (2000) 211-214
27. Graves M., and Katz J.S. Myasthenia gravis. Curr Treat Options Neurol 6 2 (2004) 163-171
28. Gajdos P., Chevret S., Clair B., Tranchant C., Chastang C., and for the Myasthenia Gravis Clinical Study Group. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol 41 (1997) 789-796
29. Qureshi A.I., Choudhry M.A., Akbar M.S., Mohammad Y., Chua H.C., Yahia A.M., et al. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology 52 (1999) 629
30. Gajdos P., Chevret S., and Toyka K. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 2 (2003) CD002277
31. Mayer S.A., and Thomas C.E. Therapy of myasthenic crisis. Crit Care Med 26 (1998) 1136-1137
32. Tripathy M., Kaushik S., and Dubey P. The effect of use of pyridostigmine and requirement of vercuronium in patients with myasthenia gravis. J Postgrad Med 49 (2003) 311-314 Discussion 314-315
33. Berroushot J., Baumann I., Kalishewski P., Sterker M., and Schneider D. Therapy of myasthenic crisis. Crit Care Med 25 7 (1997) 1228-1235
34. O'Riordan J.I., Miller D.H., Mottershead J.P., Hirsch N.P., and Howard R.S. The management and outcome of patients with myasthenia gravis treated acutely in a neurological intensive care unit. Eur J Neurol 5 (1998) 137-142
35. Kawaguchi N., et al., for The Study Group for Maysthenia Gravis in Japan. J Neurol Sci 224 (2004) 43-47
36. Panda S., Goyal V., Behari M., Singh S., and Srivastava T. Myasthenic crisis: a retrospective study. Neurol India 52 4 (2004) 453-456
37. Seybold M.E. Treatment of myasthenia gravis. In: Engle A.G. (Ed). Myasthenia gravis and myasthenic disorders vol. 8 (1999), Oxford University Press, New York 167-201
38. Pascuzzi R.M., Coslett H.B., and Johns T.R. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 15 (1984) 291-298
39. Schneider-Gold C., Gajdos P., Toyka K.V., and Hohlfeld R.R. Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev 2 (2005) CD002828
40. Bromberg M.B., and Carter O. Corticosteroid use in the treatment of neuromuscular disorders: empirical and evidence-based data. Muscle Nerve 30 (2004) 20-37
41. Marsh D.O. Adrenal therapy for neuromuscular disease including myasthenia gravis from 1896. N Y State J Med 74 11 (Oct 1974) 1974-1976
42. Shy G.M., Rabinovitch R., and McEachern D. Effects of cortisone on certain neuromuscular disorders. JAMA 144 (1950) 1353-1358
43. Engel W.K. Myasthenia gravis, corticosteroids, anticholinesterases. Ann NY Acad Sci 274 (1976) 623-630
44. Axelrod L. Glucocorticoid therapy. Medicine 55 (1976) 39-65
45. Sanders D.B. Myasthenia gravis and Lambert-Eaton myasthenic syndrome. In: Pourmand R. (Ed). Neuromuscular diseases. Expert clinicians' views vol. 13 (2001), Butterworth-Heinemann, Boston 439-457
46. Panegyres P.K., Squier M., Mills K.R., and Newsom-Davis J. Acute myopathy associated with large parenteral dose of corticosteroid in myasthenia gravis. J Neurol Neurosurg Psychiatry 56 6 (1993) 702-704
47. Yeh J.H., and Chiu H.C. Comparison between double-filtration plasmapheresis and immunoadsorption plasmapheresis in the treatment of patients with myasthenia gravis. J Neurol 247 7 (2000) 510-513
48. Yeh J.H., Chen W.H., and Chiu H.C. Double filtration plasmapheresis in the treatment of myasthenic crisis-analysis of prognostic factors and efficacy. Acta Neurol Scand 104 2 (2001) 78-82
49. Natarajan N., and Weinstein R. Therapeutic apheresis in neurology critical care. J Intensive Care Med 20 (2005) 212-225
50. Weinstein R. Therapeutic apheresis in neurological disorders. J Clin Apher 15 1-2 (2000) 74-128
51. Tesar V., Jelinkova E., Jirsa Jr. M., Bakosova M., Pitha P., and Chabova V. Soluble adhesion molecules and cytokines in patients with myasthenia gravis treated by plasma exchange. Blood Purif 18 2 (2000) 115-120
52. Psaridi-Linardaki L., Trakas N., Mamalaki A., and Tzartos S.J. Specific immunoadsorption of the autoantibodies from myasthenic patients using the extracellular domain of the human muscle acetylcholine receptor alpha-subunit. Development of an antigen-specific therapeutic strategy. J Neuroimmunol 159 1-2 (2005) 183-191
53. Flachenecker P., Taleghani B.M., Gold R., Grossmann R., Wiebecke D., and Toyka K.V. Treatment of severe myasthenia gravis with protein A immunoadsorption and cyclophosphamide. Transfus Sci 19 (1998) 43-46 [Suppl]
54. Dau P.C. Plasmapheresis therapy in myasthenia gravis. Muscle Nerve 3 6 (1980) 468-482
55. Dau P.C., Lindstrom J.M., Cassel C.K., Denys E.H., Shev E.E., and Spitler L.E. Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis. N Engl J Med 297 21 (1977) 1134-1140
56. Newsom-Davis J., Vincent A., Wilson S.G., Ward C.D., Pinching A.J., and Hawkey C. Plasmapheresis for myasthenia gravis. N Engl J Med 298 8 (1978) 456-457
57. Pinching A.J., and Peters D.K. Remission of myasthenia gravis following plasma-exchange. Lancet 2 8008 (1976) 1373-1376
58. Lisak R.P. Immunologic aspects of myasthenia gravis. Ann Clin Lab Sci 5 4 (1975) 288-293
59. Tireli H., Karlikaya G., Tutkavul K., Akpinar A., and Okay T. Myasthenia gravis: how to treat?. Acta Myol 23 3 (2004) 140-145
60. Carandina-Maffeis R., Nucci A., Marques Jr. J.F., Roveri E.G., Pfeilsticker B.H., Garibaldi S.G., et al. Plasmapheresis in the treatment of myasthenia gravis: retrospective study of 26 patients. Arq Neuro-Psiquiatr 62 2B (2004) 391-395
61. NIH Consensus. The utility of therapeutic plasmapheresis for neurological disorders. NIH Consensus Conference. JAMA 256 (1986) 1333-1337
62. Yeh J.H., Chen W.H., Huang K.M., and Chiu H.C. Prethymectomy plasmapheresis in myasthenia gravis. J Clin Apher 20 4 (Dec 2005) 217-221
63. Graves M, Katz JS. Myasthenia Gravis. Current treatment options in neurology 2004;6:163-171.
64. Korach J.M., Petitpas D., Paris B., Bourgeade F., Passerat V., Berger P., et al. Plasma exchange in France: Epidemiology 2001. Transfus Apheresis Sci 29 2 (2003) 153-157
65. Gajdos P., Simon N., de Rohan-Chabot P., Raphael J.C., and Goulon M. Long-term effects of plasma exchange in myasthenia. Results of a randomized study. Presse Med 12 15 (1983) 939-942
66. Mahalati K., Dawson R.B., Collins J.O., and Mayer R.F. Predictable recovery from myasthenia gravis crisis with plasma exchange: thirty-six cases and review of current management. J Clin Apher 14 1 (1999) 1-8
67. Dalakas M.C. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharm Ther 102 (2004) 177-193
68. Latov N., Chaudhry V., Koski C.L., Lisak R.P., Apatoff B.R., Hahn A.F., et al. Use of intravenous gamma globulins in neuroimmunologic diseases. J Allergy Clin Immunol 108 4 (2001) S126-S132
69. Selcen D., Dabrowski E.R., Michon A.M., and Nigro M.A. High-dose intravenous immunoglobulin therapy in juvenile myasthenia gravis. Pediatr Neurol 22 1 (2000) 40-43
70. Misra N., Bayry J., Ephrem A., Dasgupta S., Delignat S., Van Huyen J.P., et al. Intravenous immunoglobulin in neurological disorders: a mechanistic perspective. J Neurol 252 Suppl 1 (2005) I1-I6
71. Illa I. IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status. J Neurol 252 Suppl 1 (2005) 114-118
72. Yu Z., and Lennon V.A. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 340 3 (1999) 227-228
73. Kazatchkine M.D., and Kaveri S.V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345 10 (2001) 747-755
74. Dalakas M.C. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 291 19 (2004) 2367-2375
75. Dalakas M.C., Illa I., Dambrosia J.M., Soueidan S.A., Stein D.P., Otero C., et al. A controlled trial of high-dose intravenous immune globulin infusions as a treatment for dermatomyositis. N Engl J Med 329 27 (1993) 1993-2000
76. Wittstock M., Benecke R., and Zettl U.K. Therapy with intravenous immunoglobulins: complications and side effects. Eur Neurol 50 3 (2003) 172-175
77. Brannagan III T.H., Nagle K.J., Lange D.J., and Rowland L.P. Complications of intravenous immune globulin treatment in neurologic disease. Neurology 47 3 (1996) 674-677
78. Wolfe G.I., Barohn R.J., Foster B.M., Jackson C.E., Kissel J.T., Day J.W., et al. Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis. Muscle Nerve 26 4 (2002) 549-552
79. Hilkevich O., Drory V.E., Chapman J., and Korczyn A.D. The use of intravenous immunoglobulin as maintenance therapy in myasthenia gravis. Clin Neuropharmacol 24 3 (2001) 173-176
80. Achiron A., Barak Y., Miron S., and Sarova-Pinhas I. Immunoglobulin treatment in refractory myasthenia gravis. Muscle Nerve 23 4 (2000) 551-555
81. Jongen J.L., van Doorn P.A., and van der Meche F.G. High-dose intravenous immunoglobulin therapy for myasthenia gravis. J Neurol 245 1 (1998) 26-31
82. Lewis R.A., Selwa J.F., and Lisak R.P. Myasthenia gravis: immunological mechanisms and immunotherapy. Ann Neurol 37 Suppl 1 (1995) S51-S62
83. Namba T., Nakata Y., and Grob D. The role of humoral and cellular immune factors in neuromuscular block in myasthenia gravis. Ann NY Acad Sci 274 (1976) 493-515
84. Stricker R.B., Kwiatkowska B.J., Habis J.A., and Kiprov D.D. Myasthenic crisis. Response to plasmapheresis following failure of intravenous gamma-globulin. Arch Neurol 50 8 (1993) 837-840